Business Context and Reporting Period
Company: Radiopharm Theranostics Ltd
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: November 2025
Date of Filing: November 12, 2025
Principal Executive Office: Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia
The filing serves to disclose a public announcement made to the Australian Securities Exchange regarding the advancement of the Company's clinical trial program.
Key Financial Metrics
This Form 6-K is a current report regarding a corporate event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change disclosed is operational rather than financial:
- Clinical Trial Progress: The Company has commenced enrollment for the 3rd Cohort of its Phase 1 clinical trial for the investigational drug 177Lu-RAD204.
Guidance, Outlook, and Risks
Management Commentary: The filing references an attached exhibit (Exhibit 99.1) containing the full details of the announcement titled "RAD starts enrollment of 3rd Cohort of Phase 1 177Lu-RAD204."
Risks and Contingencies: No specific risks, contingencies, or unusual items are detailed within the body of this Form 6-K. The filing includes a standard disclaimer stating it is not deemed "filed" for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the full text of the attached Exhibit 99.1 for specific details on the Phase 1 177Lu-RAD204 trial design and patient criteria.
- Confirm the Company's cash runway and funding status in the most recent Form 20-F or quarterly report, as this filing contains no financial data.
- Monitor future updates regarding the completion of the 3rd Cohort enrollment and any subsequent safety or efficacy data releases.